Literature DB >> 17192651

Desensitization characteristics of the human alpha7nAChR/5HT3A chimera receptor.

Theo Dinklo1, Anne S Lesage, Christopher G Grantham.   

Abstract

The alpha7-nicotinic acetylcholine receptor (alpha7) is an important ionotropic receptor in the central nervous system, which becomes permeable to cations upon binding of its natural agonist acetylcholine (ACh). alpha7 kinetics are characterized by rapid activation, followed by fast desensitization of the current. As the wild-type (WT) alpha7 is difficult to express heterologously in mammalian cellular systems, frequently a more easily expressible chimera consisting of the extracellular domain of the alpha7 and the transmembrane domain of the 5HT3A receptor is used to study alpha7 pharmacology (chick alpha7/mouse 5HT3A [Eiselé et al., 1993]; human alpha7/mouse 5HT3A [Graig et al., 2004]). Desensitization characteristics of these chimera receptors have been described as intermediate compared with the fast desensitizing alpha7 and the more slowly desensitizing 5HT3A receptors. Here, we describe a fully human chimera receptor (h-alpha7/5HT3A), which is characterized by desensitization, and recovery kinetics that deviate from the human WT alpha7.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192651     DOI: 10.1385/JMN:30:1:109

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  2 in total

1.  Stable expression and characterisation of a human alpha 7 nicotinic subunit chimera: a tool for functional high-throughput screening.

Authors:  Peter J Craig; Suchira Bose; Ruud Zwart; Ruth E Beattie; Elizabeth A Folly; Laura R Johnson; Emma Bell; Non M Evans; Giovanni Benedetti; Kathy H Pearson; Gordon I McPhie; Stephen G Volsen; Neil S Millar; Emanuele Sher; Lisa M Broad
Journal:  Eur J Pharmacol       Date:  2004-10-11       Impact factor: 4.432

2.  Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities.

Authors:  J L Eiselé; S Bertrand; J L Galzi; A Devillers-Thiéry; J P Changeux; D Bertrand
Journal:  Nature       Date:  1993-12-02       Impact factor: 49.962

  2 in total
  3 in total

1.  BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

Authors:  Dalton King; Christiana Iwuagwu; Jim Cook; Ivar M McDonald; Robert Mate; F Christopher Zusi; Matthew D Hill; Haiquan Fang; Rulin Zhao; Bei Wang; Amy E Easton; Regina Miller; Debra Post-Munson; Ronald J Knox; Lizbeth Gallagher; Ryan Westphal; Thaddeus Molski; Jingsong Fan; Wendy Clarke; Yulia Benitex; Kimberley A Lentz; Rex Denton; Daniel Morgan; Robert Zaczek; Nicholas J Lodge; Linda J Bristow; John E Macor; Richard E Olson
Journal:  ACS Med Chem Lett       Date:  2017-02-08       Impact factor: 4.345

2.  Development of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists.

Authors:  Matthew D Hill; Haiquan Fang; H Dalton King; Christiana I Iwuagwu; Ivar M McDonald; James Cook; F Christopher Zusi; Robert A Mate; Ronald J Knox; Debra Post-Munson; Amy Easton; Regina Miller; Kimberley Lentz; Wendy Clarke; Yulia Benitex; Nicholas Lodge; Robert Zaczek; Rex Denton; Daniel Morgan; Linda Bristow; John E Macor; Richard Olson
Journal:  ACS Med Chem Lett       Date:  2016-12-01       Impact factor: 4.345

Review 3.  Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors.

Authors:  Roger L Papke; Nicole A Horenstein
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.